ProMIS Neurosciences Inc. — fact timeline

ProMIS Neurosciences Inc. reported financial results for quarter ended March 31, 2026.

“reporting its financial condition and financial results as of and for the quarter ended March 31, 2026.”

ProMIS Neurosciences Inc. reported the year ended December 31, 2025 results: net income $39.7 million.

“For the year ended December 31, 2025, the Company reported a net loss of $39.7 million”

ProMIS Neurosciences Inc. issued Pre-Funded Warrants (the “ Pre-Funded Warrants ”) to purchase 100,000 Common Shares of warrant to PIPE Investors (accredited investors) for the Pre-Funded Warrants have an exercise price of $14.40 per Warrant Share, are immediately exercisable and will expire when exercised in full.

“and 725,221 Common Shares were sold at a price of $12.13 per Common Share to certain affiliates and insiders of the Company. The Common Share Warrants have an exercise price of $14.40, are exercisable immediately and will expire upon the earlier of (i) within 60 days of the Milestone Event (as defined below) or (ii) February 3, 2031. The Pre-Funded Warrants”

ProMIS Neurosciences Inc. issued Common Share purchase warrants (the “ Common Share Warrants ”) to purchase 6,915,296 Common Shares of warrant to PIPE Investors (accredited investors) for the Common Share Warrants have an exercise price of $14.40, are exercisable immediately and will expire ... up to an additional approximately $100 million in gr.

“and 725,221 Common Shares were sold at a price of $12.13 per Common Share to certain affiliates and insiders of the Company. The Common Share Warrants have an exercise price of $14.40, are exercisable immediately and will expire upon the earlier of (i) within 60 days of the Milestone Event (as defined below) or (ii) February 3, 2031. The Pre-Funded Warrants”

ProMIS Neurosciences Inc. issued 6,090,075 Common Shares were sold at a price of $10.77 per Common Share, 100,000 Pre-Funded Warrants were sold at a price of $10.77 less an exercise price $0.00 of common stock to PIPE Investors (accredited investors) for $75 million in aggregate gross proceeds.

“On January 29, 2026, ProMIS Neurosciences Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Securities Purchase Agreement ”) with selected investors that qualify as “accredited investors” (the “ PIPE Investors ”), as defined in Rule 501(a) of Regulation D promulgated under the United States Securities Act of 1933, as amended (the “ Securities Act ”), for the purpose of raising approximately $75 million in aggregate gross proceeds for the Company (the “ Offering ”) before deducting placement agent fees and other expenses payable by the Company.”

ProMIS Neurosciences Inc. entered into Registration Rights Agreement with each of the PIPE Investors.

“In connection with the Securities Purchase Agreement, the Company entered into a Registration Rights Agreement with each of the PIPE Investors (the “ Registration Rights Agreement ”), pursuant to which the Company is required to prepare and file a registration statement (the “ Registration Statement ”) with the Securities and Exchange Commission (the “ SEC ”) under the Securities Act, covering the resale of the Common Shares issued to the PIPE Investors under the Securities Purchase Agreement, together with the Warrant Shares.”

ProMIS Neurosciences Inc. entered into Securities Purchase Agreement with selected investors that qualify as "accredited investors" valued at approximately $75 million (effective 2026-01-29).

“On January 29, 2026, ProMIS Neurosciences Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Securities Purchase Agreement ”) with selected investors that qualify as “accredited investors” (the “ PIPE Investors ”), as defined in Rule 501(a) of Regulation D promulgated under the United States Securities Act of 1933, as amended (the “ Securities Act ”), for the purpose of raising approximately $75 million in aggregate gross proceeds for the Company (the “ Offering ”) before deducting placement agent fees and other expenses payable by the Company.”

ProMIS Neurosciences Inc.: Reverse stock split at a 1-for-25 ratio effected via articles of amendment (effective 2025-11-28).

“Effective as of 12:01 a.m. Eastern Time on November 28, 2025, the Company filed the Articles Amendment to effect one-for-twenty-five reverse stock split”

Gavin T. Malenfant departed as Chief Operating Officer at ProMIS Neurosciences Inc..

“On February 14, 2025, ProMIS Neurosciences Inc. (the “Company”) separated with Gavin T. Malenfant as Chief Operating Officer of the Company, effective as of February 14, 2025”

ProMIS Neurosciences Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 3, 2025, ProMIS Neurosciences Inc. (“Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company’s common shares, no par value (the “Common Shares”) failed to comply with the $1 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”) based upon the closing bid price of the Common Shares for the 30 consecutive trading days prior to the date of the Minimum Bid Price Notice from Nasdaq. The Notice has n”

ProMIS Neurosciences Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 3, 2025, ProMIS Neurosciences Inc. (“Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company’s common shares”

Neil Warma was appointed as President and Chief Executive Officer at ProMIS Neurosciences Inc..

“On October 8, 2024, ProMIS Neurosciences Inc. (the “Company”) appointed Neil Warma as the President and Chief Executive Officer (“CEO”) of the Company, effective August 1, 2024.”

ProMIS Neurosciences Inc. reported the first quarter ended March 31, 2024 results: net income Net loss was $3.6 million for the quarter ended March 31, 2024.

“Net loss was $3.6 million for the quarter ended March 31, 2024, compared to a net loss of $5.0 million for the same period in 2023.”

ProMIS Neurosciences Inc. reported the fiscal year ended December 31, 2023 results: net income $13.2 million.

“Net loss was $13.2 million for the full year ended December 31, 2023, compared to a net loss of $18.1 million for full year in 2022.”

ProMIS Neurosciences Inc. entered into At The Market Offering Agreement with BTIG, LLC valued at up to $25.0 million (effective 2024-01-05).

“On January 5, 2024, Promis Neurosciences, Inc. (the “Company”) entered into an At The Market Offering Agreement (the “Agreement”) with BTIG, LLC, serving as agent (the “Agent”) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, its common shares, no par value (the “Common Stock”), having an aggregate offering price of up to $25.0 million (the “Shares”) through the Agent (the “Offering”).”

Neil Warma was appointed as President and interim Chief Executive Officer at ProMIS Neurosciences Inc..

“Effective December 30, 2023, the Board appointed Neil Warma as President and interim Chief Executive Officer and principal executive officer of the Company (the “Appointment”).”

Gail Farfel departed as President and Chief Executive Officer at ProMIS Neurosciences Inc..

“it separated with Gail Farfel, Ph.D. as President and Chief Executive Officer and principal executive officer of the Company, and as a member of the Board of Directors of the Company (the “Board”), in each case, effective as of December 30, 2023”

ProMIS Neurosciences Inc.: The Company filed articles of amendment to create a new class of Series 2 Preferred Shares, effective December 4, 2023 (effective 2023-12-04).

“Effective as of December 4, 2023, the Company filed articles of amendment (the “ Articles of Amendment ”) to amend its articles to create the new class of Series 2 Preferred Shares.”

ProMIS Neurosciences Inc. entered into Exchange Agreement with the holders of the Company's Series 1 convertible preferred shares (effective 2023-12-04).

“On December 4, 2023, Promis Neurosciences, Inc. (the “ Company ”) entered into a Share Exchange Agreement (the “ Exchange Agreement ”) with the holders (the “ Holders ”) of the Company’s Series 1 convertible preferred shares (the “ Series 1 Preferred Shares ”), pursuant to which the Series 1 Preferred Shares were exchanged for a new class of Series 2 convertible preferred shares (the “ Series 2 Preferred Shares ”).”

ProMIS Neurosciences Inc. reported the third quarter ended September 30, 2023 results: net income Net loss was $2.4 million for the quarter ended September 30, 2023.

“ProMIS Neurosciences Inc. (the "Company") issued a press release, which is available on its website (www.promisneurosciences.com under “Investors/Financial Results”), reporting its financial condition and financial results as of and for the three and nine months ended September 30, 2023.”

ProMIS Neurosciences Inc. entered into Unit Purchase Agreement with selected investors that qualify as accredited investors valued at approximately $20.4 million (effective 2023-08-21).

“On August 21, 2023, ProMIS Neurosciences Inc. (the “ Company ”) entered into an Unit Purchase Agreement (the “ Unit Purchase Agreement ”) with selected investors that qualify as “accredited investors” (the “ PIPE Investors ”), as defined in Rule 501(a) of Regulation D promulgated under the United States Securities Act of 1933, as amended (the “ Securities Act ”), for the purpose of raising approximately $20.4 million in gross proceeds for the Company (the “ Offering ”).”

ProMIS Neurosciences Inc. reported the second quarter ended June 30, 2023 results: net income Net loss was $2.3 million for the quarter ended June 30, 2023.

“On August 14, 2023, ProMIS Neurosciences Inc. (the "Company") issued a press release, which is available on its website (www.promisneurosciences.com under “Investors/Financial Results”), reporting its financial condition and financial results as of and for the three and six months ended June 30, 2023.”

ProMIS Neurosciences Inc.: Company continued from Canada Business Corporations Act to Business Corporations Act (Ontario), replacing its articles and bylaws with OBCA versions (effective 2023-07-13).

“On July 13, 2023, ProMIS Neurosciences Inc. (the “Company”) continued its existence from a corporation incorporated under the Canada Business Corporations Act (“CBCA”) into the Province of Ontario under the Business Corporations Act (Ontario) (the “OBCA”) (the “Continuance”).”

ProMIS Neurosciences Inc. shareholders approved Approval to continue the Company to the jurisdiction of the Province of Ontario under the Business Corporations Act (Ontario). at the 2023-06-29 meeting.

“Proposal No. 3: Approval to continue the Company to the jurisdiction of the Province of Ontario under the Business Corporations Act (Ontario). The votes were cast as follows by holders of Common Shares and Preferred Shares, voting together: ​ ​ ​ ​ ​ ​ ​ Votes For Votes Against Abstained Approval of Continuance into Ontario 4,537,149 ​ 103,948 ​ 6,731 ​ ​ ​ ​”

ProMIS Neurosciences Inc. shareholders approved Ratification of the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-06-29 meeting.

“Proposal No. 2: Ratification of the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The votes were cast as follows by holders of Common Shares: ​ ​ ​ ​ ​ ​ ​ ​ Votes For Votes Against Abstained Ratification of appointment of Baker Tilly US, LLP 4,294,824 ​ 99,591 ​ 1,103 ​ ​”

ProMIS Neurosciences Inc. shareholders approved Election of eight nominees to serve as directors until the 2024 annual meeting of shareholders or until his or her successor has been duly elected and qualified or until his or her earlier resignation or removal. at the 2023-06-29 meeting.

“Proposal No. 1 : Election of eight nominees to serve as directors until the 2024 annual meeting of shareholders or until his or her successor has been duly elected and qualified or until his or her earlier resignation or removal. The votes were cast as follows by holders of Common Shares: ​ ​ ​ ​ Name ​ Votes For ​ Votes Against ​ Abstained Eugene Williams 3,320,369 ​ 147,921 ​ 12,872 Neil Cashman, M.D. 3,470,265 ​ 8,611 ​ 2,286 Gail Farfel, Ph.D. 3,376,107 ​ 103,302 ​ 1,753 Patrick D. Kirwin 3,314,138 ​ 154,640 ​ 12,384 Joshua Mandel-Brehm 3,316,160 ​ 112,636 ​ 52,366 Maggie Shafmaster, Ph.D., JD 3,292,796 ​ 103,924 ​ 84,442 Neil K. Warma 3,266,932 ​ 164,174 ​ 50,056 William Wyman 3,048,981 ​ 382,124 ​ 50.057 ​ ​ Broker Non-Votes: 914,356. All eight nominees were elected.”

ProMIS Neurosciences Inc. reported the quarter ended March 31, 2023 results: net income $5.0 million.

“Net loss was $5.0 million for the quarter ended March 31, 2023, compared to $2.1 million for the same period in 2022.”

Richard Gregory departed as Director at ProMIS Neurosciences Inc..

“On March 29, 2023, Richard Gregory, a member of the Board of Directors (the “ Board ”) of ProMIS Neurosciences Inc. (the “ Company ”), notified the Company of his intent to not stand for re-election to the Board at the Company’s 2023 Annual Meeting of Stockholders (the “ Annual Meeting ”) and, as a result, his term as a director of the Company, or on any committee of the Board, will end upon the conclusion of the Annual Meeting.”

ProMIS Neurosciences Inc. reported the year ended December 31, 2022 results: net income Net loss was $18.1 million for the year ended December 31, 2022, compared to $9.8 million for the same period in 2021..

“reporting its financial condition and financial results as of and for the year ended December 31, 2022.”

ProMIS Neurosciences Inc. reported the third quarter ended September 30, 2022 results: net income Net loss was $6.0 million.

“Net loss was $6.0 million for the third quarter ended September 30, 2022, compared to $1.2 million for the same period in 2021.”

Eugene Williams departed as Chief Executive Officer at ProMIS Neurosciences Inc..

“Eugene Williams, the Company’s Chief Executive Officer and principal executive officer will step down from his officer position with the Company, effective immediately”

Gail Farfel was appointed as Chief Executive Officer at ProMIS Neurosciences Inc..

“the Board of Directors (the " Board ") of the Company approved the appointment of Gail Farfel, Ph.D. as the Company’s Chief Executive Officer, effective September 19, 2022.”